2
Clinical Trials associated with gp140 Vaccine adjuvanted with MF59C.1(Novartis Vaccines and Diagnostics)A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis Subtype C gp140 With MF59 Adjuvant in Various Vaccination Schedules in HIV-uninfected Healthy Vaccinia-naïve Adult Participants in South Africa
Sub-Saharan Africa is the region most affected by the global Human Immunodeficiency Virus (HIV) epidemic. A vaccine is the most promising preventive approach against new HIV infections. The purpose of this study is to evaluate the safety and immunogenicity of 4 experimental preventive HIV vaccine regimens in HIV-uninfected adults in South Africa.
A Phase I Open-Label Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Subtype C gp140 Vaccine With MF59 Adjuvant in Healthy, HIV-1 Uninfected Adult Participants Previously Primed or Unprimed With HIV-1 Subtype B Envelope Subunit Vaccines With MF59
The purpose of this study is to evaluate the safety and immune response to an HIV vaccine in healthy, HIV-uninfected adults who have participated in a previous HIV vaccine clinical trial and in healthy, HIV-uninfected adults who have not participated in a previous HIV vaccine clinical trial.
100 Clinical Results associated with gp140 Vaccine adjuvanted with MF59C.1(Novartis Vaccines and Diagnostics)
100 Translational Medicine associated with gp140 Vaccine adjuvanted with MF59C.1(Novartis Vaccines and Diagnostics)
100 Patents (Medical) associated with gp140 Vaccine adjuvanted with MF59C.1(Novartis Vaccines and Diagnostics)
100 Deals associated with gp140 Vaccine adjuvanted with MF59C.1(Novartis Vaccines and Diagnostics)